Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
Negative wealth shock linked to accelerated cognitive decline
Dec 26, 2023
Associations with accelerated cognitive decline and increased dementia risk were seen for white participants and those aged fewer than 65 years.
Study looks at links between anxiety disorders, benzodiazepines, dementia
Aug 14, 2023
Benzodiazepines and anxiety disorders were linked to dementia risk, but no additional risk was seen for benzodiazepines in patients with anxiety disorders.
Timing of CSF biomarker divergence for Alzheimer’s disease, normal cognition varies
Feb 21, 2024
Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline.
Lower cutoff points for Montreal cognitive assessment needed
Jan 17, 2024
A high false-positive rate was seen when used in primary care with a diverse patient population.